SEC Form 8-K filed by Anixa Biosciences Inc.
$ANIX
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/21/2025 | $10.00 | Buy | Maxim Group |
| 12/23/2022 | $8.00 | Buy | Chardan Capital Markets |
4 - Anixa Biosciences Inc (0000715446) (Issuer)
4 - Anixa Biosciences Inc (0000715446) (Issuer)
4 - Anixa Biosciences Inc (0000715446) (Issuer)
Notice of Allowance marks first Korean patent covering Anixa's breast cancer vaccine platformExpands global intellectual property coverage in markets with increasing breast cancer incidence rates and greater concentrations of younger breast cancer patientsSAN JOSE, Calif., March 9, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Korean Ministry of Intellectual Property (MOIP) has issued a Notice of Allowance for a new patent related to Anixa's breast cancer vaccine technology. This patent, exclusively licensed from Cleveland Clinic, will provide compositi
Presentation to Review Ovarian Cancer CAR-T Survival Observations and Dose Escalation, as well as Final Phase 1 Breast Cancer Vaccine DataSAN JOSE, Calif., March 2, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host its 2026 Annual Meeting of Stockholders (the "Meeting") on Tuesday, March 10, 2026, at 10:00 a.m. Pacific Time in a virtual format. The Meeting will be open to all interested parties, including non-stockholders. Following th
Dr. Conejo-Garcia is the co-inventor of Anixa's FSHR-mediated CAR-T technologySAN JOSE, Calif., Feb. 23, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Jose Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine and the co-inventor of Anixa's CAR-T technology, will be a keynote speaker at the South Carolina Clinical & Translational Research (SCTR) Institute 2026 Retreat: Cell-Based Therapies from Discovery to Translation, on Friday, March 6, 2026.
4 - Anixa Biosciences Inc (0000715446) (Issuer)
4 - Anixa Biosciences Inc (0000715446) (Issuer)
4 - Anixa Biosciences Inc (0000715446) (Issuer)
8-K - Anixa Biosciences Inc (0000715446) (Filer)
10-Q - Anixa Biosciences Inc (0000715446) (Filer)
8-K - Anixa Biosciences Inc (0000715446) (Filer)
Maxim Group initiated coverage of Anixa Biosciences with a rating of Buy and set a new price target of $10.00
Chardan Capital Markets initiated coverage of Anixa Biosciences with a rating of Buy and set a new price target of $8.00
HC Wainwright & Co. initiated coverage of Anixa Biosciences with a rating of Buy and set a new price target of $11.00
SAN JOSE, Calif., Oct. 7, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Suyasha Gupta as Senior Director of Clinical Development. In this role, Ms. Gupta will work closely with Dr. Pamela Garzone, Chief Development Officer, to oversee the Company's ongoing Phase 1 breast cancer vaccine and Phase 1 ovarian cancer CAR-T therapy clinical trials, as well as the upcoming Phase 2 breast cancer vaccine clinical trial. Suyasha Gupta is
Dr. Amit Kumar interviewed in latest episode, 'The Vaccine That Could End Breast Cancer' SAN JOSE, Calif., May 6, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced a podcast interview of Anixa Chairman and CEO Dr. Amit Kumar by oncologist Dr. Sanjay Juneja, with more than 500,000 followers through his media brand 'TheOncDoc.' The interview is broadly available on podcast platforms and can be viewed now on YouTube. In the "Target: Cancer
SAN JOSE, Calif., April 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Sanjay Juneja, MD to its Cancer Business Advisory Board. Anixa Chairman and CEO Dr. Amit Kumar stated, "Dr. Juneja is an accomplished medical oncologist who has earned status as a top media personality on cancer prevention and treatment innovations. His influence has earned him invitations to help shape healthcare policy, and, most important
– Antigen-specific T cell responses were observed at all dose levels – – IFNγ and IL-17, immune-mediated biomarkers of T cell activation, increased over time from baseline – – Vaccine was safe and well tolerated – – Conference call to commence today at 6:30 p.m. ET – SAN JOSE, Calif., Dec. 6, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced new and updated positive results from the Phase 1 clinical trial of its breast cancer vaccine. The trial is being conducted in collaboration with Cleveland Clinic with funding by a grant from the U.S. Department of Defense.
– Data to be released at approximately 6:00 p.m. ET, following presentation at 2023 SABCS – – Conference call to commence at 6:30 p.m. ET – SAN JOSE, Calif., Dec. 6, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, will publicly release new data this evening from the ongoing Phase 1 clinical trial of its breast cancer vaccine, which was presented for the first time today at the 2023 San Antonio Breast Cancer Symposium ("SABCS"). All interested parties are invited to join an upcoming conference call today at 6:30 pm ET to discuss the data.
SC 13D - Anixa Biosciences Inc (0000715446) (Subject)
SC 13D/A - Anixa Biosciences Inc (0000715446) (Subject)
SC 13D/A - Anixa Biosciences Inc (0000715446) (Subject)